Overview

Open Label Extension to Bridging Study CTBM100C2303

Status:
Completed
Trial end date:
2011-10-06
Target enrollment:
Participant gender:
Summary
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa (P. aeruginosa) at enrollment into CTBM100C2303.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Tobramycin